Amendments to the Abstract:

Please delete the abstract and replace it with the following new abstract:

This application relates to matrix metalloprotease inhibitors having the generalized formula

in which r is 0-2, T is selected from

and R⁴⁰ is a mono-or bi-heterocyclic structure. More particularly, the present application claims the various stereoisomeric forms of 4-(4'-choloro-biphenyl-4-yl)-4-oxo-2-[2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)ethyl]butyric acid, as well as their pharmaceutically acceptable salts. Pharmaceutical compositions containing these compounds, and methods for inhibiting matrix metalloprotease activity in mammals such as humans and for treating various conditions by administering such compounds are also claimed.